About BioNTech SE - American Depositary Shares (BNTX)
BioNTech SE is a biotechnology company focused on developing and providing transformative therapies for patients suffering from serious diseases. It is primarily known for its pioneering work in mRNA-based vaccines, particularly in the field of infectious diseases and cancer immunotherapy. By leveraging its proprietary technology platform, BioNTech aims to create personalized and innovative treatments that harness the body’s natural immune response. The company is committed to advancing scientific research and bringing novel therapeutics to market, working collaboratively with partners in the pharmaceutical industry and academic institutions to address unmet medical needs globally. Read More
MAINZ, Germany, December 18, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subsequent offering period (the “Subsequent Offering Period”) of the exchange offer (the “Offer”) for all outstanding shares of CureVac expired today at 12:01 a.m. Eastern Time. With the successful acquisition, BioNTech intends to further complement its capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. The acquisition builds on BioNTech’s proven track record and established position in the global mRNA industry and supports the execution of the Company’s oncology strategy which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L1 and VEGF-A, which is being jointly developed with Bristol Myers Squibb Company (NYSE: BMY, “BMS”).
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall Street's expectations. The announcement immediately sent shockwaves through the market, with Pfizer's stock experiencing a notable decline as investors
MAINZ, Germany, and PRINCETON, USA, December 9, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced the first interim data from a global randomized Phase 2 trial (NCT06449222) evaluating pumitamig (BNT327/BMS986545), an investigational bispecific antibody targeting PD-L1 and VEGF-A, plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer (“TNBC”) irrespective of PD-L1 expression levels.
MAINZ, Germany, December 3, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”), representing approximately 81.74% of CureVac’s issued and outstanding shares, were validly tendered and not properly withdrawn prior to the expiration of the initial offering period at 9:00 a.m. Eastern Time on December 3, 2025. As a result, the minimum condition for the exchange offer (the “Offer”) has been satisfied, and all validly tendered shares have been accepted. All closing conditions related to the completion of the post-offer reorganization have now been satisfied. BioNTech will now proceed to deliver BioNTech American Depositary Shares (“ADSs”) (and/or cash in lieu of fractional BioNTech ADSs) to the holders of CureVac shares who have tendered their shares, to close the transaction, as set out in more detail in the offer documents (as referred to below).
MAINZ, Germany, and ROCKVILLE, USA, December 6, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today presented data from the non-pivotal dose-confirmation stage of the global randomized Phase 3 trial PRESERVE-003 (NCT05671510) for gotistobart (also known as BNT316 or ONC-392), a tumor microenvironment-selective regulatory T cell (“Treg”) depletion candidate, targeting CTLA-4 in patients with metastatic squamous non-small cell lung cancer (sqNSCLC). Gotistobart demonstrated a clinically meaningful overall survival (“OS”) benefit compared to standard-of-care chemotherapy and a manageable safety profile in sqNSCLC patients whose disease had progressed following anti-PD-(L)1 therapy and platinum-based chemotherapy. Data from the non-pivotal stage of the trial are being presented today in an oral presentation at the IASLC ASCO 2025 North America Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer in Chicago, Illinois, USA.
MAINZ, Germany, November 26, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the approval of matters relating to the exchange offer (the “Offer”) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”) at the extraordinary general meeting (“EGM”) held by CureVac on November 25, 2025. At the EGM, over 99.16% of votes cast by CureVac shareholders were in favor of the proposals relating to the Offer. BioNTech expects to complete the pending Offer as soon as reasonably practicable.
MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S.
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a
MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EST (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced it had commenced its public exchange offer (the “Offer”) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”). The Offer is being made pursuant to the previously announced purchase agreement between BioNTech and CureVac, dated as of June 12, 2025 (the “Purchase Agreement”). Upon closing, the transaction will bring together two pioneers in mRNA science with complementary capabilities and technologies to advance the development of innovative and transformative investigational mRNA-based cancer immunotherapies for patients in need.
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
